chartexchange

DVAX
Dynavax Technologies Corporation
stockNASDAQ

InactiveFeb 9, 2026
15.50USD0.000%(0.00)7,102,420
Loading…
Loading…
Sector
Healthcare
Industry
Biotechnology
HQ
Emeryville, California, USA
Nov 10, 2014 · 1-for-10 (reverse)
DVAX Profile

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.

DVAX Performance
PeriodPriceDateChange